The Government of Canada is investing $1.9m through the COVID-19 Immunity Task Force (CITF) to fund an extension of CanPath’s COVID-19 Antibody Study over a longer period of time, allowing for additional collection of blood samples and questionnaires. The CanPath COVID-19 Antibody Study is implemented in collaboration with CanPath’s regional cohorts, including Atlantic PATH, CARTaGENE (Quebec), the Ontario Health Study, the Manitoba Tomorrow Project, Alberta’s Tomorrow Project, and the BC Generations Project.
CanPath is a national population health research platform that follows the health of 330,000 volunteer Canadians (or approximately 1% of the population). Its pan-Canadian COVID-19 Antibody Study will now collect a second dried blood spot sample from over 20,000 Canadians, aged 30 and older. Researchers will test the samples for presence and level of antibodies to SARS-CoV-2, produced in response to either vaccination or past infection with the novel coronavirus.
Please click here for additional details: https://bit.ly/3I6lWE5